SOLASCURE
SolasCure aims to support healthcare professionals with wound care products that significantly improve the health and wellbeing of patients with chronic wounds.
SOLASCURE
Industry:
Biopharma Biotechnology Health Care Medical
Founded:
2017-06-20
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.solascure.com
Total Employee:
11+
Status:
Active
Contact:
+441223827959
Email Addresses:
[email protected]
Total Funding:
20.77 M USD
Technology used in webpage:
IPv6 Google Apps For Business Gravatar Profiles Google DNS Google Domains Google Cloud DNS
Similar Organizations
Urovant Sciences
Urovant Sciences is a global biopharmaceutical company focused on developing novel therapies for urologic conditions.
Current Advisors List
Current Employees Featured
Founder
Investors List
Jonathan Milner
Jonathan Milner investment in Series A - SolasCure
François Fournier
François Fournier investment in Series A - SolasCure
Development Bank of Wales
Development Bank of Wales investment in Series A - SolasCure
Seneca Partners
Seneca Partners investment in Series A - SolasCure
Bionova Capital
Bionova Capital investment in Series A - SolasCure
Eva Pharma
Eva Pharma investment in Series A - SolasCure
BRAIN
BRAIN investment in Series A - SolasCure
BRAIN
BRAIN investment in Seed Round - SolasCure
Official Site Inspections
http://www.solascure.com Semrush global rank: 6.42 M Semrush visits lastest month: 378
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.186
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "SolasCure"
ABOUT US | SolasCure
With more than 20 years of both strategic and operational experience in clinical research and development of pharmaceuticals and medical devices, Antoinette brings a deep understanding …See details»
SolasCure - Crunchbase Company Profile & Funding
Organization. SolasCure . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... SolasCure is a biotechnology / biopharma company developing a breakthrough in wound bed …See details»
SolasCure - LinkedIn
SolasCure | 1,368 followers on LinkedIn. Transforming chronic wound care with a breakthrough wound therapeutic | Chronic wounds affect ~100m people around the world, impacting quality of life ...See details»
SolasCure Company Profile 2024: Valuation, Funding
SolasCure was founded in 2017. Where is SolasCure headquartered? SolasCure is headquartered in Cambridge, United Kingdom. What is the size of SolasCure? SolasCure has 22 total employees. What industry is SolasCure in? …See details»
SolasCure Company Profile - Office Locations, Competitors ... - Craft
SolasCure (also known as AURASE) is a biotech company engaged in the development of healthcare products. It leverages biomimicry and evidence-based medicine to develop …See details»
BRAIN AG announces the creation of SolasCure Ltd.… | BRAIN …
Aug 22, 2018 SolasCure Limited (Company Nº 10826246) aims to support healthcare professionals with wound care products that significantly improve the health and wellbeing of …See details»
SolasCure - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
SolasCure - VentureRadar
Our proprietary technology leverages biomimicry and evidence-based medicine to develop treatments for patients with chronic wounds. ... Find out more about SolasCure, …See details»
SolasCure - Contacts, Employees, Board Members, Advisors
Organization. SolasCure . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 4. Number of Board …See details»
Company Spotlight: Solascure - SyndicateRoom
Solascure are working to revolutionise wound care. Its proprietary technology leverages biomimicry and evidence-based medicine to develop treatments for patients with chronic …See details»
SolasCure’s David Fairlamb recognised at TOPRA Awards for …
Jan 16, 2023 With more than 30 years of global regulatory affairs experience working in industry and consultancy supporting small molecule, biologics, medical devices and combination …See details»
SolasCure Demonstrates Proof-of-Concept in Phase Ila Safety Trial …
Dec 14, 2023 Andy Weymann M.D., newly appointed Chairman of the Board, SolasCure, said: “I am delighted to join the SolasCure team, especially at such an exciting phase of growth. The …See details»
SolasCure Publishes Phase IIa Clinical Trial Report in Leading …
CAMBRIDGE, England, March 04, 2024--SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound care, has today announced …See details»
SolasCure Demonstrates Proof-of-Concept in Phase lla Safety Trial …
Dec 12, 2023 CAMBRIDGE, England — SOLASCURE Ltd (SolasCure), a biotechnology company developing a hydrogel containing tarumase (provisional INN), a recombinant enzyme …See details»
SolasCure receives £15m investment - Lifescience Industry News
Aug 13, 2021 SolasCure is developing proprietary technology leveraging biomimicry and evidence-based medicine to empower health care professionals to treat patients with chronic …See details»
NEWS - SolasCure
SolasCure and U.S. Army Institute of Surgical Research collaborate for combat wound care. READ MORE. THOUGHT LEADERSHIP. 21 Aug 2024. Wound Care Voices: Why the Battle …See details»
SolasCure Publishes Phase IIa Clinical Trial Report in Leading …
Mar 4, 2024 SolasCure’s Aurase Wound Gel has shown in this publication positive safety and proof-of-concept results, which bring this product a significant step closer to providing relief to …See details»
SolasCure announces final closing of GBP 10.9m (c. USD 13.3m) …
Mar 27, 2023 Please use one of the following formats to cite this article in your essay, paper or report: APA. SolasCure. (2023, March 27). SolasCure announces final closing of GBP 10.9m …See details»
SolasCure demonstrates proof-of-concept in Phase lla safety trial …
Dec 12, 2023 SolasCure’s Aurase Wound Gel, a hydrogel containing an enzyme cloned from medical maggots, aims to facilitate debridement, reduce bacterial biofilm, and promote wound …See details»